HC Wainwright Issues Pessimistic Forecast for MetaVia (NASDAQ:MTVA) Stock Price

Posted by Donald Scott on Mar 27th, 2026

MetaVia (NASDAQ:MTVA – Get Free Report) had its price target cut by equities researchers at HC Wainwright from $40.00 to $20.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other equities analysts have also recently commented on MTVA. Wall Street Zen lowered MetaVia from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $26.50.

Get Our Latest Report on MTVA

MetaVia Trading Down 4.8%

Shares of MTVA traded down $0.06 during midday trading on Friday, reaching $1.26. 59,626 shares of the company were exchanged, compared to its average volume of 262,272. MetaVia has a 1-year low of $1.22 and a 1-year high of $23.10. The stock has a 50-day moving average price of $1.85 and a 200-day moving average price of $6.85. The company has a market cap of $2.76 million, a price-to-earnings ratio of -0.15 and a beta of 0.33.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent reporting period. Institutional investors and hedge funds own 1.37% of the company’s stock.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.